Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 1, 2003Clinical Infectious Diseases

Voriconazole: A New Triazole Antifungal Agent

View Full Paper
Ask AI
Bookmark
Share

Authors

LJLeonard B. JohnsonHenry Ford HospitalCKCarol A. KauffmanUniversity of North Carolina at Chapel Hill

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Johnson et al. (2003) studied this question.

synapsesocial.com/papers/69e34fdcdfa4bcab6eb73707https://doi.org/10.1086/367933
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species1996 · 124 citations
  2. 2Efficacy and Safety of Voriconazole in the Treatment of Acute Invasive Aspergillosis2002 · 847 citations
  3. 3Successful treatment of ocular invasive mould infection (fusariosis) with the new antifungal agent voriconazole2000 · 109 citations
  4. 4Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole2001 · 133 citations
  5. 5In Vitro Activities of Four Novel Triazoles against <i>Scedosporium</i> spp2001 · 182 citations